GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Change In Other Working Capital

Fennec Pharmaceuticals (STU:RV41) Change In Other Working Capital : €23.10 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Fennec Pharmaceuticals Change In Other Working Capital?

Fennec Pharmaceuticals's Change In Other Working Capital for the quarter that ended in Mar. 2024 was €23.10 Mil. It means Fennec Pharmaceuticals's Other Working Capital increased by €23.10 Mil from Dec. 2023 to Mar. 2024 .

Fennec Pharmaceuticals's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Fennec Pharmaceuticals's Other Working Capital increased by €0.00 Mil from Dec. 2022 to Dec. 2023 .

Fennec Pharmaceuticals Change In Other Working Capital Historical Data

The historical data trend for Fennec Pharmaceuticals's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Change In Other Working Capital Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.14 - - -

Fennec Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 23.10

Fennec Pharmaceuticals Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €23.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (STU:RV41) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (STU:RV41) » Definitions » Change In Other Working Capital
Comparable Companies
TSX:MDNA TSXV:NGEN NEOE:CYBN TSX:EPRX XCNQ:ACOG TSX:ONC TSXV:ARCH XCNQ:METX TSX:SVA TSX:TH OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
FENC:USA FRX:Canada
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Website
https://www.fennecpharma.com
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (STU:RV41) Headlines

No Headlines